Pfizer Investigational Site
Ruddington Fields, Nottingham, NG11 6JS, United Kingdom
NCT Number: NCT02142920
The purpose of the study is to characterize how PF-05212384 is metabolized in the body following a single intravenous dose of radioactively labeled drug ([14C]-PF-05212384).
Looking for future studies?
Notify Me30 year–65 year
Male
Interventional
Phase 1
Ruddington Fields, Nottingham, NG11 6JS, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single 89 mg Dose via 30 minute IV infusion
Time frame: 0.5 hours
Time frame: 0.5 hours
Time frame: 9 Days
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: 9 days
AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
Time frame: 9 days
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 9 days
CL is a quantitative measure of the rate at which a drug substance is removed from the body.
Time frame: 9 days
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
Pfizer
Industry
A Phase One, Open-Label Single-Radiolabeled Dose Study To Investigate The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details